Abstract Details

Title A Phase 2 Efficacy Study of an Oral, Potent and Selective T-Type Calcium (Cav3) Modulator in Essential Tremor Patients (T-CALM): Design and Dose Selection Rationale

Topic Movement Disorders

Presentation(s) P6 - (-)

Poster/Presentation
Number 060

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Spyridon Papapetropoulos, MD, PhD (SPIRIDON PAPAPETROPOULOS, MD, PHD) PRESENTER	Dr. Papapetropoulos has received personal compensation for serving as an employee of Vigil Neuroscience . Dr. Papapetropoulos has received personal compensation for serving as an employee of Bionomics Ltd. Dr. Papapetropoulos has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Lipocine Inc. Dr. Papapetropoulos has stock in Vigil Neuroscience. Dr. Papapetropoulos has stock in Lipocine. Dr. Papapetropoulos has stock in Bionomics Ltd.
Yuri Maricich	No disclosure on file
Margaret S. Lee, PhD	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��